World10 minutes ago (Oct 19, 2021 06:22AM ET)
© Reuters. FILE PHOTO: A healthcare worker fills a syringe with a dose of Bharat Biotech’s COVID-19 vaccine called COVAXIN, during the coronavirus disease (COVID-19) vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India
By Krishna N. Das
NEW DELHI (Reuters) – India has delayed committing supplies of vaccine to the COVAX global sharing platform, two sources told Reuters on Tuesday, a day after one of its key backers, the WHO, said the agency could not “cut corners” to approve a domestically developed vaccine.
The world’s biggest vaccine maker resumed exports of COVID-19 doses this month for the first time since April. It has sent about 4 million to countries such as neighbouring Bangladesh and Iran, but none to COVAX.
On Monday, in the run-up to an Oct. 26 meeting on Covaxin, India’s first domestically developed COIVD-19 vaccine, the World Health Organization (WHO) said it could not “cut corners” in the approval decision.
One of the sources said it was “frustrating” that India had yet to confirm any supply to COVAX, despite a promise last month by the health minister to meet the commitment to COVAX and others during the quarter to December.
The sources, who have been briefed on the export talks, declined to be identified as they were not authorised to speak on the subject.
The Serum Institute of India (SII), the world’s biggest vaccine manufacturer, has contracts to supply hundreds of millions of doses of a licensed version of the AstraZeneca (NASDAQ:) vaccine to COVAX and countries such as Bangladesh.
Its output of the vaccine has more than tripled since April, to reach 220 million doses a month now.
India’s health ministry, SII and COVAX co-leads, the WHO and GAVI, did not respond to requests for comment.
Delayed supplies to COVAX could disrupt inoculation drives in many African nations that rely on it for vaccine supplies.
Indian government officials have said they are confident the WHO will soon approve an emergency-use listing for Covaxin, which makes up 11% of the 990 million vaccine doses given in India, with the rest mostly from AstraZeneca.
A few weeks ago, Adar Poonawalla, the chief executive of SII, told the Telegraph newspaper that his company would recommence exports to COVAX in October.
“Initially these supplies will be small, but by January 2022, once we have satisfied domestic demands … we will see large volumes go to COVAX,” he added.
Before India halted overseas vaccine shipments in April so as to meet domestic demand, it donated or sold more than 66 million COVID-19 doses, including Covaxin.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.